Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma has launched DistributeRx, a new U.S.-focused healthcare solutions business that creates a direct-to-patient channel to simplify prescription fulfilment and improve access to medicines. The platform uses digital workflows, transparent cash-pay pricing and Mayne Pharma’s Adelaide Apothecary and CoAssist Pharmacy to route prescriptions efficiently, reduce reliance on traditional intermediaries and enhance affordability and adherence.
The DistributeRx offering also includes manufacturer services such as co-pay program optimisation, enhanced fulfilment solutions and direct-to-pharmacy contracting aimed at improving product economics and supporting sustainable profitability. Management positions the initiative as a key step in Mayne Pharma’s disintermediation strategy, strengthening its position in women’s health and dermatology and tapping into the fast-growing global ePharmacy and virtual pharmacy market.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an Australia-based specialty pharmaceutical company with a strong focus on women’s health and dermatology products. The company develops, manufactures and commercialises branded, authorised generic and generic medicines, and is increasingly targeting the growing U.S. market through digital and direct-to-patient distribution models.
YTD Price Performance: -18.33%
Average Trading Volume: 448,514
Technical Sentiment Signal: Sell
Current Market Cap: A$206.4M
Learn more about MYX stock on TipRanks’ Stock Analysis page.